Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Allergan Pharmaceuticals International Limited operates within the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 5 pending office actions distributed across 3 distinct art units. This distribution suggests a diverse range of pharmaceutical or biological subject matter under review, requiring expertise from 3 distinct art units within the patent office. The presence of 5 pending office actions indicates an active and ongoing prosecution effort for the company.
Prosecution is handled by 5 distinct examiners, matching the total number of pending actions. ROZOF, TIMOTHY R is the busiest examiner for the company, currently managing 1 pending office action. The involvement of 5 distinct examiners means that each application is receiving an independent review from a different individual. This can provide a variety of perspectives on the company's pharmaceutical innovations, rather than having the portfolio's fate determined by a single examiner's interpretation.
The spread across 5 distinct examiners and 3 distinct art units within the Biotechnology & Pharmaceuticals sector highlights the complexity of the company's filings. For practitioners, this means that prosecution strategies must be tailored to the specific expectations of multiple examiners and art units. The fact that the busiest examiner, ROZOF, TIMOTHY R, only holds 1 pending office action underscores the high level of examiner diversity in the current portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| FONTAINHAS, AURORA M | 1 | 37.9% | +49.2% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16558488 | HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS | MARTIN, PAUL C | 26d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998763 | COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 71d overdue |
| 16558488 | HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS | MARTIN, PAUL C | 26d overdue |
| 18768496 | TREATMENT OF MIGRAINE | ROZOF, TIMOTHY R | — |
| 18640418 | FORMATION OF BONE | FONTAINHAS, AURORA M | — |
| 17637799 | TROPOELASTIN FOR USE IN TREATMENT OF ACNE SCARRING | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1654 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18768496 | TREATMENT OF MIGRAINE | ROZOF, TIMOTHY R | — | §103DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18640418 | FORMATION OF BONE | FONTAINHAS, AURORA M | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 17998763 | COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 1647 | §103DP | Non-Final OA | 71d overdue | Pending | Nov 14, 2022 |
| 17637799 | TROPOELASTIN FOR USE IN TREATMENT OF ACNE SCARRING | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Feb 23, 2022 |
| 16558488 | HIGH POTENCY PANCREATIN PHARMACEUTICAL COMPOSITIONS | MARTIN, PAUL C | 1653 | §103§112Other | Non-Final OA | 26d overdue | Pending | Sep 03, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial